BridgeMD
New treatment option for Ph-Like
Official title ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL
ClinicalTrials.gov ID: NCT07454226
What this study is testing
What is Olverembatinib?
Olverembatinib is an investigational medicine, being studied as a potential treatment for ph-like.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This open-label, non-randomized, phase II exploratory study aims to evaluate the efficacy and safety of combining pathway-specific tyrosine kinase inhibitors with chemotherapy and venetoclax in patients with newly diagnosed Ph-like acute lymphoblastic leukemia (ALL). Patients are stratified by genetic alteration: those with ABL class fusions (ABL1, ABL2, PDGFRA, PDGFRB) receive olverembatinib, while those with JAK pathway alterations (CRLF2 rearrangement, JAK mutation/fusion, EPOR fusion, SH2B3 deletion, IL7R mutation) receive Gecacitinib.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 14 to 60
You may be able to join if
- Age ≥14 years and ≤60 years, regardless of gender
- ECOG performance status score ≤2
- Male and female participants of childbearing potential agree to and adopt effective contraceptive measures
- Criteria for major organ function assessment: total bilirubin \ 45% as shown by cardiac ultrasound
You likely can't join if
- Pregnant women
- Severe uncontrolled active infections
- Mental illnesses that may hinder the completion of treatment or informed consent
- Other conditions deemed unsuitable for this study by the investigator
The study team makes the final eligibility decision.
Where it's taking place
- Tianjin, Tianjin Municipality, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 14 years to 60 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Tianjin, Tianjin Municipality, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.